Evotec SE (EVT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Evotec SE (EVT) has a cash flow conversion efficiency ratio of -0.084x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-67.56 Million ≈ $-78.98 Million USD) by net assets (€800.14 Million ≈ $935.44 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Evotec SE - Cash Flow Conversion Efficiency Trend (2003–2024)
This chart illustrates how Evotec SE's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Evotec SE (EVT) total liabilities for a breakdown of total debt and financial obligations.
Evotec SE Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Evotec SE ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Pierre et Vacances SA
PA:VAC
|
-0.722x |
|
Jiangsu Allfavor Intelligent Circuits Technology CO.Ltd
SHE:300964
|
0.006x |
|
Shengtak New Material Co Ltd
SHE:300881
|
-0.103x |
|
Barrett Business Services Inc
NASDAQ:BBSI
|
0.160x |
|
Sansiri Public Company Limited
BK:SIRI-R
|
0.021x |
|
Amsterdam Commodities NV
AS:ACOMO
|
-0.097x |
|
Zhuzhou Tianqiao Crane Co Ltd
SHE:002523
|
0.041x |
|
GUANGDONG HK GR BA.HD-01
F:16H0
|
N/A |
Annual Cash Flow Conversion Efficiency for Evotec SE (2003–2024)
The table below shows the annual cash flow conversion efficiency of Evotec SE from 2003 to 2024. For the full company profile with market capitalisation and key ratios, see Evotec SE stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €952.52 Million ≈ $1.11 Billion |
€18.22 Million ≈ $21.30 Million |
0.019x | -41.21% |
| 2023-12-31 | €1.12 Billion ≈ $1.31 Billion |
€36.44 Million ≈ $42.60 Million |
0.033x | -80.98% |
| 2022-12-31 | €1.19 Billion ≈ $1.39 Billion |
€203.11 Million ≈ $237.45 Million |
0.171x | +92.82% |
| 2021-12-31 | €1.38 Billion ≈ $1.61 Billion |
€122.24 Million ≈ $142.91 Million |
0.089x | +43.84% |
| 2020-12-31 | €725.01 Million ≈ $847.62 Million |
€44.72 Million ≈ $52.28 Million |
0.062x | -30.30% |
| 2019-12-31 | €477.03 Million ≈ $557.70 Million |
€42.22 Million ≈ $49.35 Million |
0.088x | -75.93% |
| 2018-12-31 | €424.88 Million ≈ $496.73 Million |
€156.24 Million ≈ $182.66 Million |
0.368x | +1026.64% |
| 2017-12-31 | €331.75 Million ≈ $387.85 Million |
€10.83 Million ≈ $12.66 Million |
0.033x | -89.63% |
| 2016-12-31 | €213.94 Million ≈ $250.11 Million |
€67.36 Million ≈ $78.75 Million |
0.315x | +276.39% |
| 2015-12-31 | €187.09 Million ≈ $218.73 Million |
€15.65 Million ≈ $18.30 Million |
0.084x | +448.94% |
| 2014-12-31 | €158.38 Million ≈ $185.17 Million |
€-3.80 Million ≈ $-4.44 Million |
-0.024x | -157.25% |
| 2013-12-31 | €158.97 Million ≈ $185.85 Million |
€6.66 Million ≈ $7.78 Million |
0.042x | -46.57% |
| 2012-12-31 | €152.55 Million ≈ $178.34 Million |
€11.96 Million ≈ $13.98 Million |
0.078x | +13.75% |
| 2011-12-31 | €147.25 Million ≈ $172.14 Million |
€10.15 Million ≈ $11.86 Million |
0.069x | +916.62% |
| 2010-12-31 | €132.64 Million ≈ $155.07 Million |
€899.00K ≈ $1.05 Million |
0.007x | +103.46% |
| 2009-12-31 | €111.49 Million ≈ $130.34 Million |
€-21.85 Million ≈ $-25.55 Million |
-0.196x | +28.84% |
| 2008-12-31 | €149.86 Million ≈ $175.20 Million |
€-41.28 Million ≈ $-48.26 Million |
-0.275x | -48.33% |
| 2007-12-31 | €170.55 Million ≈ $199.39 Million |
€-31.67 Million ≈ $-37.03 Million |
-0.186x | -176.14% |
| 2006-12-31 | €137.18 Million ≈ $160.37 Million |
€-9.22 Million ≈ $-10.78 Million |
-0.067x | -367.85% |
| 2005-12-31 | €148.67 Million ≈ $173.81 Million |
€-2.14 Million ≈ $-2.50 Million |
-0.014x | +95.23% |
| 2004-12-31 | €61.73 Million ≈ $72.17 Million |
€-18.60 Million ≈ $-21.74 Million |
-0.301x | +22.58% |
| 2003-12-31 | €36.03 Million ≈ $42.12 Million |
€-14.02 Million ≈ $-16.39 Million |
-0.389x | -- |
About Evotec SE
Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just " Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, immunology, pain and inflammati… Read more